Onconetix, Inc. (ONCO): Total Liabilities
$9.16M
As of 2025-12-31
$2.96M
As of 2026-06-30
+32.7%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.16M | -50.7% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $18.57M | -15.1% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $21.88M | +457.8% | 2025-06-02, Balance as of period end |
| 2022-12-31 | $3.92M | +139.4% | 2024-04-11, Balance as of period end |
| 2021-12-31 | $1.64M | n/a | 2023-03-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | 2025-12-31 | $9.16M | -50.7% |
| Rallybio Corp (RLYB) | 2025-12-31 | $4.30M | -33.3% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $15.74M | +48.8% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $1.57M | +30.1% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $8.64M | -24.4% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.99M | +10.1% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $1.61M | +19.2% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $29.63M | +5.4% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $140.38M | +6.8% |
Compare ONCO, RLYB, RFL, LEXX side by side · Screen every company in Pharmaceutical Preparations ↗